Orion Pharma Articles
Europe’s CHMP adopts positive opinions on Dexdor, Incivo, Plenadren, Vyndaqel and Zytiga; backs extensions
23 July 2011
US FDA questions safety of Novartis/Orion’s Stalevo due to possible increased cardiovascular risk
23 August 2010
Orion's 1st-half net income inches up 4%
22 August 2005
Orion posts 6.4% sales decline
16 May 2005
Italy OKs 79 new drugs, plans R&D promotion
7 March 2005
Orion Group announces 43.4% profit increase
28 February 2005
Orion sees sales fall for first nine months
15 November 2004
Trial to assess Stalevo in delaying dyskinesia
13 September 2004
Orion Pharma eyes UK market environment
7 June 2004
First-quarter 2004 results for Orion Group
24 May 2004
Orion/Abbott expand levosimendan accord
26 April 2004
Orion chief Risto Miettunen resigns
5 April 2004
Orion's Stalevo available in the UK
22 December 2003
Orion halts Simdax MAA in Germany
13 October 2003
John Garrigan joins Bradley's Doak unit
18 August 2003
Orion's PD therapy is approved by FDA
30 June 2003
Further news on Orion's restructuring strategy
16 June 2003
Orion negotiating restructuring
9 June 2003
Sales down at Orion; R&D unit abandoned
2 June 2003
Orion profits under pressure from R&D costs
24 February 2003
Update: Blow to Orion as deramciclane fails
24 February 2003
Blow to Orion as deramciclane fails in Phase III anxiety studies
24 February 2003
New president at Orion Diagnostica
24 June 2002
Miettunen appointed executive VP at Orion
3 June 2002
Orion 1st-qtr net profit increases 62.4%
13 May 2002
Orion/Innothera HRT deal
18 March 2002
Changes at Orion Pharma
4 March 2002
Orion posts modest sales growth
25 February 2002
Orion benefits from Pharmacia payment
7 November 2001
Orion Pharma 2nd-qtr net sales up 8.1%
13 August 2001
Pharma profits well down at Orion
9 May 2001
Orion's Simdax gets mixed EU opinion
17 April 2001
New R&D site for Orion
8 March 2001
Orion in-house drugs now 28% of turnover
23 February 2001
Orion Pharma to take over BASF Pharma R&D facility in the UK
14 February 2001
Overseas sales boost Orion Pharma
10 November 2000
Novartis/Orion seek entacapone use in early Parkinson's disease
18 October 2000
Actelion well-placed for success with endothelin antagonists for heart
21 September 2000
Orion to develop combo Parkinson's drug
7 September 2000
Orion Pharma licenses Nestorone
26 April 2000
Orion's Zotepine, Comtess In UK
26 November 1998
UK Industry Code Of Practice Report
1 September 1997
Entacapone And Tolcapone Near Market Introduction
26 March 1997
UK Industry Code Of Practice In 1996
24 March 1997
Sandoz To License Orion Parkinson's Drug
4 March 1996
Orion Pharma appointment
30 October 1995
Sanofi Launches New HRT Approach In UK
8 May 1995
Showing 1-54 of 54 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
